Supplementary Figure 14: RG108 treatment does not change visual responses.

(a) Baseline activity of each unit of the different groups was not affected by RG108 or vehicle treatment (Nondep 77 units, MD3d untreated 77 units, MD3d RG108 71 units, MD3d vehicle 76 units. One way ANOVA F = 0.35, P = 0.79). (b) Responsiveness for each unit of the different groups (Nondep 77 units, MD3d untreated 77 units, MD3d RG108 71 units, MD3d vehicle 76 units) was expressed as a ratio between peak response frequency (measured on peristimulus time histograms as the maximum response of each unit) and baseline discharge frequency. No statistical difference is present between all groups (one way ANOVA F = 0.19, P = 0.91). (c) Receptive field size (RFS) was not altered by RG108 or vehicle infusion in MD3d critical period mice (Nondep 77 units, MD3d untreated 77 units, MD3d RG108 71 units, MD3d vehicle 76 units). None of the treatments significantly altered RFS (one way ANOVA F = 0.37, P = 0.77). Receptive fields were measured on peristimulus time histograms elicited by light bars of optimal orientation drifting in the visual field. The width of the part of visual field eliciting cell discharge greater than spontaneous discharge plus two SD was taken as RFS. Error bars represent SEM.